Helen Fong, Ph.D.
About Helen Fong, Ph.D.
Helen Fong, Ph.D., is a Scientist III at Sangamo Therapeutics, Inc., with extensive experience in genetic manipulation of pluripotent stem cells. She has held various research positions in prominent organizations and has a strong educational background in Microbiology and Biomedical Sciences.
Current Role at Sangamo Therapeutics
Helen Fong, Ph.D., currently holds the position of Scientist III at Sangamo Therapeutics, Inc. since 2021. In this role, she contributes to the company's research initiatives focused on gene therapy and genomic medicine. Her work involves utilizing her expertise in stem cell biology and genetic manipulation to advance therapeutic strategies.
Previous Experience at Sangamo Therapeutics
Prior to her current position, Helen Fong worked at Sangamo Therapeutics, Inc. as Scientist II from 2018 to 2020. During this time, she was involved in various projects related to the application of genomic technologies in therapeutic development. Her experience in this role laid the foundation for her current responsibilities.
Experience at AllCells, LLC and Gladstone Institutes
Helen Fong served as a Senior Research Scientist at AllCells, LLC from 2015 to 2018, where she focused on stem cell research. Before that, she worked at Gladstone Institutes as a Research Scientist for 10 months in 2015, and later as a Postdoctoral Fellow from 2011 to 2014. Her roles at these institutions contributed to her extensive knowledge in genetic manipulation and stem cell biology.
Educational Background
Helen Fong earned her Bachelor of Science in Microbiology from the University of California, Davis, where she studied from 2001 to 2005. She then pursued a Ph.D. in Biomedical Sciences, specializing in Stem Cell Biology, at the University of California, Irvine from 2005 to 2011. Her education provided a strong foundation for her research career.
Expertise in Stem Cell Research
Helen Fong possesses extensive experience in the genetic manipulation of pluripotent stem cells, including genome editing and clonal cell analysis. She is adept in differentiating human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) into various cell types. Additionally, she is skilled in deriving induced pluripotent stem cells (iPSCs) from blood and fibroblast cells.